PRICIEST HOMES
A look at how the luxury home market shifted in 2020. PAGE 13
CHICAGOBUSINESS.COM | FEBRUARY 8, 2021 | $3.50
Citadel’s risk: Prying open the black box
fpo
Reddit-fueled court action could force disclosure of closely guarded intel
Ken Griffin
BY STEVE DANIELS
Janet Hayes
5th time’s a charm?
AP IMAGES
All it takes is one judge. Citadel remains caught in the swirl of anger and confusion over the would-be Reddit revolution in stock investing. As both a participant in the short selling that newly minted day traders attempted to combat and profit from as well as the leading market maker for the trading app many of them used, Ken Griffin’s investment empire is a starring player in the drama, the ending
Crate & Barrel has had a revolving door of CEOs in the past decade, with Janet Hayes the latest. Her challenge: Ushering the retailer into a new era. BY ALLY MAROTTI FOR THE FIRST 50 YEARS of Crate & Barrel’s existence, the retailer only had two CEOs. In the past decade, however, it has churned through five. The current chief executive, retail veteran Janet Hayes, was quietly hired at the Northbrook-based retailer six months ago. Will she have better luck than her predecessors? Industry observers are optimistic. Crate & Barrel entered the pandemic with a strong online pres-
ence, allowing it to capitalize on increasing home furnishing sales. But Hayes will face challenges as the economy recovers, and must steer Crate into a new era of retail. Gordon Segal, who co-founded the company with his wife, Carole, in 1962 and was CEO until 2008, says Hayes’ strong background in See CRATE on Page 17
of which defies easy prediction. Chicago-based Citadel (the hedge fund) and Citadel Securities (the market maker) are defendants in at least 20 lawsuits around the country so far—most of them purported class actions seeking to recover large trading losses incurred by investors See CITADEL on Page 17
AbbVie sheds light on life after Humira CEO predicts 2 new drugs will mostly fill the gap BY STEPHANIE GOLDBERG AbbVie is finally offering answers to questions investors have been asking since the drugmaker spun off from Abbott Laboratories in 2012: How badly will the loss of patent protection for AbbVie’s top-selling drug hurt and how long will it take to recover? For the first time, AbbVie last month gave detailed projections for revenue trends after Humira loses protection from generic competition in the U.S. CEO
Richard Gonzalez told an investor conference that sales will decline when Humira copycats invade the U.S. market in 2023, rise modestly in 2024 and reach high-single-digit growth in 2025 and beyond. The prediction of a rapid rebound dispels some of the uncertainty that has hovered over AbbVie as it nears the end of a long exclusivity period for its blockbuster drug. Humira sales peaked at $19.9 billion in 2018, See ABBVIE on Page 23
NEWSPAPER l VOL. 44, NO. 6 l COPYRIGHT 2021 CRAIN COMMUNICATIONS INC. l ALL RIGHTS RESERVED
GREG HINZ
THE TAKEAWAY
Some biz leaders are starting to scout for an alternative to Lightfoot. PAGE 2
The new head of the Chicago Association of Realtors honors her son’s life. PAGE 6